Idiopathic Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Idiopathic Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Inhaled NO in IPF and COPD During 6 Minute Walk Test [Phase 2]
Phase 2 trial exploring inhaled nitric oxide effects in COPD and idiopathic pulmonary fibrosis during the six-minute walk test.
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 trial evaluating safety, tolerability, and efficacy in idiopathic pulmonary fibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-09-13Clinical Trial Update: IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
Observational study of IPF (FIBRONET) completed; results posted in 2019.
-
FDA approval · 2019-09-06FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for OFEV (nintedanib) from Boehringer Ingelheim Pharmaceuticals, expanding its approved use.
-
CLINICAL_TRIALS trial_result · 2019-08-12Clinical Trial Update: Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging [Phase 1]
Phase 1 trial update for single doses of GSK3008348 in idiopathic pulmonary fibrosis with PET imaging; study terminated with results posted …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment [Phase 4]
Phase 4 trial evaluating nintedanib effects on extracellular matrix turnover biomarkers in idiopathic pulmonary fibrosis with limited forced…
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain
A completed real-world chart review study describing the clinical profile of idiopathic pulmonary fibrosis patients treated with nintedanib …
-
FDA approval · 2019-07-31FDA Approved: ESBRIET — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Esbriet (pirfenidone) filed by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2019-07-15Clinical Trial Update: Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 trial update investigating the effect of Fostair on biomarkers of platelet adhesion in idiopathic pulmonary fibrosis (IPF).
-
CLINICAL_TRIALS trial_result · 2019-06-06Clinical Trial Update: Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
Phase 2 rollover study update for BIBF 1120 in idiopathic pulmonary fibrosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-05-22Clinical Trial Update: Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 trial assessing a lysophosphatidic acid receptor antagonist for idiopathic pulmonary fibrosis has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
Phase 2 study evaluating safety and tolerability of PBI-4050 in patients with idiopathic pulmonary fibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-03-04Clinical Trial Update: A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination [Phase 4]
A phase 4 trial comparing blood levels of nintedanib and pirfenidone when given separately or in combination for idiopathic pulmonary fibros…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Cromolyn Detection of Silent Aspiration [Phase 1]
A Phase 1 study evaluating cromolyn for detecting silent aspiration was terminated; it addressed conditions including gastroesophageal reflu…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis [NA]
Completed clinical trial evaluating home-based pulmonary rehabilitation for idiopathic pulmonary fibrosis.
-
CLINICAL_TRIALS research · 2019-02-08Clinical Trial Update: Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
An update on Boehringer Ingelheim's expanded access program for nintedanib in idiopathic pulmonary fibrosis, noting that the program is no l…
-
CLINICAL_TRIALS trial_result · 2019-01-24Clinical Trial Update: Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects [Phase 1]
A Phase 1 trial evaluating tolerability, pharmacokinetics, and the food effect of ZL-2102 in healthy male subjects.
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis [NA]
A completed clinical trial evaluating patient-reported symptom monitoring and spirometry via the patientMpower platform in idiopathic pulmon…
-
CLINICAL_TRIALS research · 2019-01-23Clinical Trial Update: Impact of Air Pollution on Chronic Respiratory Diseases
This clinical trial update from Seoul National University Hospital describes a study examining how air pollution influences chronic respirat…
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis [Phase 3]
Phase 3 clinical trial of ART-123 for acute exacerbation of idiopathic pulmonary fibrosis has completed, according to the trial registry upd…
-
CLINICAL_TRIALS trial_result · 2019-01-11Clinical Trial Update: Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment [Phase 3]
A Phase 3 trial evaluated the efficacy and safety of nintedanib given with sildenafil in patients with idiopathic pulmonary fibrosis and adv…
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
Phase 2 trial evaluating PRM-151 in idiopathic pulmonary fibrosis has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2018-11-13Clinical Trial Update: Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis [Phase 2, Phase 3]
Phase 2/3 clinical trial investigating vascular reactivity in idiopathic pulmonary fibrosis was terminated; results posted in 2018.
-
FDA approval · 2018-11-09FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OFEV (nintedanib) submitted by Boehringer Ingelheim Pharmaceuticals, Inc., indicating an app…
-
CLINICAL_TRIALS trial_result · 2018-08-24Clinical Trial Update: A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
Phase 2 clinical trial update for lebekizumab in idiopathic pulmonary fibrosis has completed with posted results.